Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial
Key Takeaways
- No on-the-record statement from Tyrus (George Murdoch) confirming or denying GLP-1 medication use has been located as of May 2026
- His visible body has shifted at points during his Fox News tenure, which is what drives the search interest, but visible change is not evidence of medication
- Tyrus's background as a professional wrestler creates a body-composition profile that does not map cleanly onto standard BMI assumptions
- Speculation about large men's bodies follows different cultural patterns than speculation about women's bodies, and that is worth naming directly
- The honest answer to the headline question is "we do not know," and that answer is more useful than confident guessing in either direction
Direct answer
Tyrus has not publicly confirmed or denied GLP-1 medication use. No interview, podcast statement, or social post has been located in which he addresses semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, or Zepbound directly. His visible body has changed across his television tenure, but visible change is consistent with many causes, including training, dietary adjustment, the demands of a daily commentary schedule, and ordinary fluctuation in a former pro athlete in his early fifties.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- Who Tyrus is, briefly
- What Tyrus has actually said
- What drives the search interest
- The body-composition problem with former wrestlers
- What GLP-1 use would look like in someone with Tyrus's profile
- What it likely is not, if it is not GLP-1
- How male celebrity speculation differs from female speculation
- The decision framework: large men considering GLP-1 therapy
- The contrary view: why "we don't know" is sometimes a dodge
- FAQ
- Sources
Who Tyrus is, briefly
George Murdoch performs and writes under the ring name Tyrus. He competed in professional wrestling from the mid-2000s through the mid-2010s, including a run in WWE as Brodus Clay and later work with Impact Wrestling and the National Wrestling Alliance. He transitioned into political commentary and joined Fox News as a contributor and panelist, appearing regularly on Gutfeld! and hosting his own program Maintaining with Tyrus on Fox Nation, along with the Tyrus Podcast.
His public body has been visible across two distinct careers: an in-ring presence built around being one of the largest performers on the roster, and a televised commentary presence where he sits at a desk in a suit. The two contexts produce very different visual reads. A 360-pound man in tights flexing is read differently than a 320-pound man in a tailored blazer sitting still.
That context matters when people are eyeballing whether he is smaller now.
What Tyrus has actually said
As of May 2026, we have not located a clear on-the-record statement from Tyrus on GLP-1 medications. He has occasionally referenced training, mobility, and the physical demands of his shift from in-ring work to a desk job, but the framing has stayed general.
On the Tyrus Podcast, he has talked about diet adjustments, the difficulty of training while running a daily television schedule, and the way his body responded to leaving the wrestling industry. He has not, in episodes we have reviewed, named semaglutide, tirzepatide, or any GLP-1 brand.
This is different from celebrities who have explicitly denied use (Ariana Grande, Kim Kardashian) and different from celebrities who have explicitly confirmed (Oprah Winfrey, Serena Williams, Chelsea Handler). Tyrus sits in the third category: no statement either way.
That category is the most common one. Most public figures whose bodies change do not address the question publicly. Their silence is not evidence in either direction.
What drives the search interest
Search volume for "is tyrus on ozempic" reflects a few specific dynamics:
| Driver | What it does |
|---|---|
| Visible body change on a daily show | Viewers watch the same person multiple times a week and notice subtle differences. Small changes that would be invisible in a stranger become legible. |
| Wrestling alumni pattern | Several former wrestlers have publicly confirmed GLP-1 use. The pattern primes viewers to wonder about others. |
| Cultural saturation | Since 2022, any visible change in a public figure now triggers GLP-1 speculation by default. The category is the explanation that comes to mind first. |
| Polarized audience | Tyrus appears on Fox News commentary; speculation comes from across the political spectrum, with different framings depending on the source. |
None of these drivers are evidence about Tyrus specifically. They explain why the question is being asked, not whether the answer is yes.
The body-composition problem with former wrestlers
BMI is a poor instrument for evaluating former professional wrestlers. A man who carried high lean mass through a competitive career often retains substantial muscle even after retiring. His BMI may sit well above 30 while his body-fat percentage is not in the range that BMI implies.
This matters for GLP-1 eligibility in two directions:
Direction 1: BMI can overstate adiposity. A former wrestler at BMI 38 might have a body-fat percentage that, in a sedentary man, would correspond to a BMI in the low 30s. The therapeutic indication based on BMI alone may not fit the underlying physiology.
The 2024 American Association of Clinical Endocrinologists guidance recommends supplementing BMI with waist circumference and metabolic markers when assessing former athletes. A clinician working with a patient like Tyrus would likely look at fasting glucose, hemoglobin A1c, lipid panel, blood pressure, and waist circumference rather than rely on BMI alone.
Direction 2: Lean mass preservation is a higher priority. GLP-1 weight loss includes 25 to 40 percent lean mass loss per the STEP 1 trial body-composition substudy (Wilding et al. 2021). For a former wrestler whose identity, livelihood, and joint health depend partly on muscle, lean-mass loss matters more than it would for a sedentary patient. Protein intake, resistance training, and slow titration become more important.
Whether or not Tyrus is on a GLP-1 medication, his profile is the kind that a thoughtful clinician would handle carefully.
What GLP-1 use would look like in someone with Tyrus's profile
For a man in Tyrus's general physical category (former pro wrestler, large frame, in his fifties, working a high-visibility daily television job), a typical GLP-1 trajectory would look something like this:
- Start at a low dose (semaglutide 0.25 mg weekly or tirzepatide 2.5 mg weekly) and titrate slowly to manage nausea
- Visible weight change beginning around weeks 8 to 12, with the bulk of loss occurring between weeks 16 and 36
- Expected total loss in the 14 to 22 percent range over a year, with tirzepatide trending higher than semaglutide per SURMOUNT-1 vs STEP 1 data
- Common side effects: nausea, occasional vomiting, constipation, reduced appetite, lower alcohol tolerance
- Facial volume change becomes visible after roughly 20 to 30 pounds of loss, varying by individual
If Tyrus were on a GLP-1 medication during 2024 or 2025, the visible change would be gradual rather than sudden. A daily-television schedule makes adherence easier in some ways (consistent routine) and harder in others (frequent meals on set, hospitality food during travel for live events).
The clinical signature people often look for, including specific food-noise language, mentions of nausea, or descriptions of reduced appetite, has not appeared in public statements from Tyrus that we have located. The absence is consistent with either non-use or with use without public discussion. Plenty of patients on GLP-1 therapy do not talk about it publicly.
What it likely is not, if it is not GLP-1
If Tyrus's visible body changes do not reflect medication, the most plausible alternative explanations include:
Training shifts. Transitioning from in-ring work to a desk job changes daily caloric expenditure substantially. A wrestler training and traveling burns more than a commentator sitting at a desk. Weight redistribution and overall mass change can follow that shift, in either direction, over months to years.
Dietary adjustment. Cutting back on alcohol, processed food, or late-night eating produces visible change over time. Many former wrestlers describe deliberately reworking their diet after retirement to protect joints and cardiovascular health.
Age-related muscle loss. Men in their fifties lose roughly 1 percent of muscle mass per year without resistance training. For someone who carried 50 to 80 pounds of lean mass above the male average during his competitive years, even normal age-related sarcopenia produces visible difference over a five-year window.
Hormonal change. Testosterone declines naturally with age and affects body composition. Men in their fifties may pursue clinical management of low testosterone, which can shift body composition independent of GLP-1 therapy.
Lighting and wardrobe. A studio lighting change or a more tailored suit can make the same body look 15 pounds different on camera. Not all visible change is body change.
Any of these can produce the kind of slow visible shift that drives speculation. None requires a medication explanation.
How male celebrity speculation differs from female speculation
The pattern of GLP-1 speculation around men differs from the pattern around women in ways worth naming:
| Dimension | Pattern around women | Pattern around men |
|---|---|---|
| Volume | High, often driven by red-carpet appearances | Lower, driven by visible changes on daily shows or in body-focused contexts |
| Framing | Often moralized ("she cheated"); body talk treated as fair game | Less moralized; weight loss often framed as positive achievement |
| Tone | Frequently hostile or invasive | Mixed; sometimes admiring, sometimes mocking |
| Default assumption | Denial is suspicious | Denial is often accepted |
Tyrus's case sits in the male pattern. The speculation is real but lower volume than equivalent female cases at his level of visibility. The framing tends to be less judgmental, though the political polarization of Fox News commentary creates its own cross-current.
This is not an argument that male public figures deserve more privacy. It is a description of how the speculation pattern actually operates. Recognizing the pattern helps separate the question of what is true from the question of how the question itself is being asked.
The decision framework: large men considering GLP-1 therapy
If you are a large man wondering whether GLP-1 medication is appropriate for you, the framework looks like this:
Step 1: Confirm your category.
- BMI 30 or higher: FDA-approved indication for Wegovy or Zepbound (and off-label for Ozempic or Mounjaro)
- BMI 27 to 29.9 with qualifying comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea): FDA-approved indication
- BMI below 27: Not indicated for weight management
Step 2: Account for body composition. If you are a former athlete or carry substantial muscle mass, ask your clinician about waist circumference and metabolic markers in addition to BMI. The FDA criteria are written around BMI, but the clinical conversation can be more nuanced.
Step 3: Map the muscle-preservation plan. Plan to consume roughly 1.2 to 1.6 grams of protein per kilogram of body weight per day during weight loss. Continue resistance training at a frequency you can actually sustain. Expect to lose some lean mass; the goal is to minimize it.
Step 4: Discuss contraindications. Personal or family history of medullary thyroid carcinoma or MEN2 is an absolute contraindication. Active pancreatitis is a contraindication. Severe gastroparesis is a contraindication. Your clinician will work through these.
Step 5: Decide on brand or compounded. Brand Wegovy or Zepbound carries FDA approval and consistent supply. Compounded semaglutide or tirzepatide is not FDA-approved, is prepared by a state-licensed 503A compounding pharmacy in response to an individual prescription, and may cost less. The choice has trade-offs your clinician can walk through.
Step 6: Plan the off-ramp. Discuss in advance what happens if you stop the medication. STEP 4 (Rubino et al. 2021) showed that patients who stopped semaglutide regained roughly two-thirds of lost weight over 1 year. Build the maintenance plan before you start, not after.
The contrary view: why "we don't know" is sometimes a dodge
The honest answer to "Is Tyrus on Ozempic?" is "we don't know." That answer is correct as a matter of evidence. But it can also be a way of avoiding the harder cultural questions the search implies.
Counter-argument 1: Public figures opt into scrutiny. Tyrus chose a public-facing career. His body is on television several hours a week. The argument that speculation about his body is intrusive runs into the reality that he has built a brand partly around physical presence. The privacy claim is weaker for him than for, say, a private accountant whose neighbor wonders about her weight loss.
Counter-argument 2: Silence allows commercial advantage. If a public figure does use GLP-1 medication and stays silent while marketing books, supplements, training programs, or anything tangentially related to physical condition, the silence is not neutral. It allows the audience to attribute results to whatever the public figure is selling. The non-answer can be commercially useful.
Counter-argument 3: The category effect is real. Public figures who quietly use GLP-1 medication while implying the results came from discipline contribute to the cultural setup where ordinary people feel they should be able to achieve the same outcomes without medication. The privacy of the individual has knock-on effects on the public.
None of these arguments tell us whether Tyrus, specifically, uses GLP-1 medication. They do explain why "we don't know" can feel unsatisfying.
The honest position is to hold both: we genuinely do not know in his case, and the broader cultural question of celebrity disclosure is worth taking seriously regardless of any single person's situation.
FAQ
Is Tyrus on Ozempic? No on-the-record statement from Tyrus confirming or denying GLP-1 medication use has been located as of May 2026. Speculation is based on visible body changes during his Fox News tenure, not on disclosure. Without medical records, prescription history, or a direct statement, the honest answer is that we do not know.
Has Tyrus lost weight? Tyrus has appeared at different sizes across his wrestling career and his Fox News commentary tenure. He has occasionally referenced training, diet adjustments, and physical conditioning on his podcast and on air, but he has not disclosed specific weight figures or attributed visible changes to any medication.
What has Tyrus said about his health? On the Tyrus Podcast and on Gutfeld!, he has touched on training, recovery, and the demands of moving from professional wrestling to a daily commentary schedule. He has not, to our knowledge, made on-the-record statements about GLP-1 medications, semaglutide, tirzepatide, or Ozempic specifically.
How tall is Tyrus and how much does he weigh? Promotional materials from his wrestling career listed him at 6 feet 7 inches and around 365 pounds. His current weight is not publicly disclosed. Visible changes on television may reflect actual body change, lighting, wardrobe, posture, or some combination.
Why are people asking if Tyrus is on Ozempic? His visible body has changed at points during his Fox News tenure. Since 2022, almost any visible weight change in a public figure now triggers GLP-1 speculation. The pattern reflects cultural saturation of GLP-1 coverage, not specific evidence about Tyrus.
Have other professional wrestlers confirmed GLP-1 use? Some wrestling alumni have spoken publicly about pharmacological weight management. The category exists. That does not establish anything specific about Tyrus, but it does explain why his name comes up alongside others in the same general profession.
Are GLP-1 medications used by large men? Yes. Tirzepatide and semaglutide are FDA-approved for adults with BMI 30 or higher, or BMI 27 with qualifying comorbidities. Men in the BMI 30+ range, including former athletes carrying high lean mass, may meet criteria.
Does former-wrestler body composition affect GLP-1 outcomes? Former pro wrestlers often carry substantial lean mass alongside fat mass. BMI alone can overstate adiposity in these patients. A clinician will typically use waist circumference, DEXA when available, or metabolic markers to confirm that pharmacotherapy is appropriate.
What is Ozempic face and would a man like Tyrus show it? Facial volume loss occurs with any meaningful weight loss, not specifically with GLP-1 medications. A man with a large frame losing 30 to 50 pounds would show facial change regardless of method. The change is more visible in already-lean faces than in faces with substantial subcutaneous fat at baseline.
Should I take Ozempic if I look like Tyrus? Eligibility is not about looking like anyone. It is about your BMI, your comorbidities, and your clinician's assessment. Ask your clinician whether you meet criteria and whether GLP-1 therapy fits your medical history.
Is it appropriate to speculate about a Fox News commentator's medical decisions? Public figures opt into a degree of scrutiny, but medical decisions remain private. Speculation without evidence spreads misinformation and can pressure people to disclose health information they would prefer to keep private. Curiosity is human; insisting on an answer is not.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: STEP 4. JAMA. 2021.
- American Association of Clinical Endocrinologists. Clinical Practice Guideline on Pharmacotherapy in Obesity. 2024.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction: SURMOUNT-4. JAMA. 2024.
- FDA Drug Approvals Database. Semaglutide and Tirzepatide indications.
- Endocrine Society. Clinical Practice Guideline: Pharmacological Management of Obesity. 2022.
- Heymsfield SB et al. Body Composition Assessment in Adults: Recommendations Beyond BMI. Obesity Reviews. 2023.
- Pearl RL. Weight Bias and Stigma. Obesity. 2023.
- FDA. Drug Compounding under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with independent licensed clinicians and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medications directly. Clinical judgments belong to the prescriber.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by state-licensed 503A compounding pharmacies in response to an individual prescription. Compounded preparations have not been reviewed by the FDA for safety, efficacy, or quality and are not interchangeable with brand-name products such as Ozempic, Wegovy, Mounjaro, or Zepbound.
Editorial Independence and Results Notice. Editorial content is produced independently of any commercial relationship with the public figures discussed. Outcomes described in clinical trials reflect averages within a study population and do not predict any individual's experience.
Trademark and Affiliation Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Fox News, Gutfeld!, Fox Nation, and Maintaining with Tyrus are trademarks of their respective owners. FormBlends has no affiliation with, endorsement from, or sponsorship by Tyrus, Fox News, Novo Nordisk, or Eli Lilly.